Αρχική World News Study Updating Meta-analysis Confirms the Deleterious Effect of Systemic Antibiotics on Immune...

Study Updating Meta-analysis Confirms the Deleterious Effect of Systemic Antibiotics on Immune Checkpoint Inhibitor Efficacy

An update of meta-analyses confirmed previous reports of poorer outcomes following immune checkpoint inhibitor (ICI) treatment in patients exposed to systemic antibiotics. Researchers reported at the ESMO Immuno-Oncology Virtual Congress 2020, held from 9 to 12 December 2020, that the deleterious impact upon ICI treatment was strongest with antibiotic used that occurred directly prior to or immediately after the initiation of ICI therapy.

Gérard Zalcman of the Department of Thoracic Oncology and CIC1425, Hôpital Bichat-Claude Bernard, Assistance Publique Hôpitaux de Paris, Université de Paris in Paris, France, presented an update of systematic reviews and meta-analyses studying the association between antibiotic exposure, progression-free survival (PFS) and overall survival (OS) in cancer patients treated with ICIs.

The updated meta-analysis included all new studies published up to October 2020 that were identified by searching Medline, the Cochrane Library and major oncology conferences’ proceedings. Studies were included when they assessed the impact of antibiotic use on the clinical outcomes of patients treated for cancer with ICIs and provided hazard ratios (HRs) or Kaplan–Meier curves for OS or PFS based upon antibiotic exposure. Pooled HRs for OS and PFS were calculated according to cancer type and the time window of antibiotic exposure.

The database search uncovered data from 70 independent cohorts that were published from 2018 to October 2020 and included in the meta-analysis. Of these, 65 independent cohorts reported OS data representing 23,146 patients and 45 cohorts provided PFS results for 14,689 patients.

The OS (pooled HR 1.65; 95% confidence interval [CI] 1.46-1.87) and PFS (pooled HR 1.44; 95% CI 1.27-1.64) data from these cohorts confirmed that survival was significantly decreased in patients receiving ICIs for cancer who were also exposed to antibiotics.

The investigators also performed a detailed analysis in subgroups based on the cancer type and on the antibiotic exposure time window. These findings suggest that the deleterious effect of antibiotics is greatest for non-small-cell lung carcinoma and melanoma and when the exposure occurs shortly before and after the start of the ICI treatment.

Study-Updating-Meta-analysis-Confirms-the-Deleterious-Effect-of-Systemic-Antibiotics-on-Immune-Checkpoint-Inhibitor-Efficacy

Antibiotic exposure time window.

© Gérard Zalcman.

Conclusions

The authors of this poster concluded that this work confirmed the previously reported deleterious effect of antibiotic use on ICI treatment outcomes, taking into account the latest publications in the field.

They advise that this issue warrants further research to uncover if the effect will stand with first-line line use of ICI together with chemotherapies and/or other approved combinations, and to elucidate the mechanisms at stake, as well as to improve patient care.

Funding from Da Volterra was disclosed.

Reference

50P – Zalcman G, Crespin A, Cervesi J, et al. Update of systematic reviews and meta-analyses studying the association between antibiotic use and clinical outcomes of cancer patients treated with immune checkpoint inhibitors. ESMO Immuno-Oncology Virtual Congress 2020 (9-12 December).

Source

NEWSLETTER

Συμπληρώστε το email σας για να λαμβάνετε τις σημαντικότερες ειδήσεις από το ogkologos.com

Βρείτε μας

2,449ΥποστηρικτέςΚάντε Like
57ΑκόλουθοιΑκολουθήστε

Διαβαστε Επίσης

Καρκίνος και Κορωνοϊός (COVID-19) ΜΕΡΟΣ Α

Εάν είστε καρκινοπαθής, το ανοσοποιητικό σας σύστημα μπορεί να μην είναι τόσο ισχυρό όσο κανονικά, έτσι μπορεί να ανησυχείτε για τους κινδύνους που σχετίζονται...

ΠΑΓΚΟΣΜΙΑ ΗΜΕΡΑ ΚΑΡΚΙΝΟΥ

Η Παγκόσμια Ημέρα Κατά του Καρκίνου καθιερώθηκε με πρωτοβουλία της Διεθνούς Ένωσης κατά του Καρκίνου (UICC), που εκπροσωπεί 800 οργανώσεις σε 155 χώρες του...

ΕΞΕΛΙΞΕΙΣ ΣΤΗ ΘΕΡΑΠΕΙΑ ΤΟΥ ΜΗ-ΜΙΚΡΟΚΥΤΤΑΡΙΚΟΥ ΚΑΡΚΙΝΟΥ ΤΟΥ ΠΝΕΥΜΟΝΑ (ΜΜΚΠ)

ΕΞΕΛΙΞΕΙΣ ΣΤΗ ΘΕΡΑΠΕΙΑ ΤΟΥ ΜΗ-ΜΙΚΡΟΚΥΤΤΑΡΙΚΟΥ ΚΑΡΚΙΝΟΥ ΤΟΥ ΠΝΕΥΜΟΝΑ (ΜΜΚΠ) Γράφει ο Δρ Παπαδούρης Σάββας, Παθόλογος-Ογκολόγος   Ο ΜΜΚΠ βρίσκεται αναλογικά στο 80% και πλέον του συνολικού...

Διατρέχουν όντως οι καρκινοπαθείς μεγαλύτερο κίνδυνο λόγω κοροναϊού;

Σε πρακτικό επίπεδο, τα δεδομένα των σχετικών μελετών υποδηλώνουν ότι η χημειοθεραπεία ή οι άλλες αντι-νεοπλασματικές θεραπείες δεν αυξάνουν σημαντικά τον κίνδυνο θνησιμότητας από...

FDA: Η ακτινοβολία των smartphones δεν προκαλεί καρκίνο

Σε μια νέα έκθεσή της, η Υπηρεσία Τροφίμων και Φαρμάκων (FDA) των ΗΠΑ αναφέρει ότι επανεξέτασε τις σχετικές επιστημονικές έρευνες που δημοσιεύθηκαν τα τελευταία...

Νέα ανακάλυψη, νέα ελπίδα για τον καρκίνο

Ένα νεοανακαλυφθέν τμήμα του ανοσοποιητικού μας συστήματος θα μπορούσε να αξιοποιηθεί για την αντιμετώπιση όλων των ειδών καρκίνου, σύμφωνα με επιστήμονες του πανεπιστημίου Cardiff...
- Advertisment -

Ροή Ειδήσεων

Despite Proven Safety of HPV Vaccines, More Parents Have Concerns

October 22, 2021, by NCI Staff Credit: National Cancer Institute Despite more than 15 years of consistent evidence that HPV vaccines are safe and effective, a...

FDA Approves Atezolizumab as Adjuvant Treatment for Non-Small Cell Lung Cancer

On 15 October 2021, the US Food and Drug Administration (FDA) approved atezolizumab (Tecentriq, Genentech, Inc.) for adjuvant treatment following resection and platinum-based chemotherapy...

Breast Cancer Survivor Uses Comedy to Spread Awareness and Address Disparities

Suzette Simon lost her mother to breast cancer. In 2020, she learned that she had the disease, as well. Realizing how much harder breast...

Why Wearing Comfortable Clothes During Cancer Treatment Matters

Voices on Cancer is an award-winning Cancer.Net Blog series where advocates share their stories and the lessons they have learned about being a cancer advocate. Cindy Trice is...

Breast cancer surgery: ‘I’m proud of the tattoos inked across my chest’

Wendy had a double mastectomy in 2017 and remained flat. “When the consultant told me, I remember crying and saying that I have 2 young...

EMA Recommends Granting a Marketing Authorisation for Zanubrutinib for the Treatment of Waldenström’s Macroglobulinaemia

On 16 September 2021, the European Medicines Agency’s (EMA’s) Committee for Medicinal Products for Human Use adopted a positive opinion, recommending the granting of...